Icon

POSLUMA (NDA216023)- (25ML (8-158mCi/ML))

FLOTUFOLASTAT F-18 GALLIUM BLUE EARTH
25ML (8-158mCi/ML)
No No
2041-Nov-27 2028-May-25
None None
None No
POSLUMA is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: • with suspected metastasis who are candidates for initial definitive therapy • with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.
0 0 0
Total Other Developers None
Drugs with Suitability No
25ML (8-158mCi/ML) ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.